This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kunii, K. Articles by Lutterbach, B. Search for Related Content PubMed PubMed Citation Articles by Kunii, K. Articles by Lutterbach, B.

FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival

¹ Pharmacology, ² Cancer Biology and Therapeutics, and ³ Cancer Pathways, Merck Research Laboratories, Boston, Massachusetts; and ⁴ Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan

Requests for reprints: Bart Lutterbach, Cancer Biology and Therapeutics, BMB 10-122, Merck Research Laboratories, 33 Avenue Louis Pasteur, Boston, MA 02115. Phone: 617-992-2038; Fax: 617-992-2412; E-mail: bart_lutterbach{at}merck.com.

Key Words: kinase • receptor • tyrosine

We have identified a critical role for amplified FGFR2 in gastric cancer cell proliferation and survival. In a panel of gastric cancer cell lines, fibroblast growth factor receptor 2 (FGFR2) was overexpressed and tyrosine phosphorylated selectively in FGFR2-amplified cell lines KatoIII, Snu16, and OCUM-2M. FGFR2 kinase inhibition by a specific small-molecule inhibitor resulted in selective and potent growth inhibition in FGFR2-amplified cell lines, resulting in growth arrest in KatoIII cells and prominent induction of apoptosis in both Snu16 and OCUM-2M cells. FGFR2-amplified cell lines also contained elevated phosphotyrosine in EGFR, Her2, and Erbb3, but the elevated phosphorylation in EGFR could not be inhibited by gefitinib or erlotinib. We show that the elevated EGFR, Her2, and Erbb3 phosphotyrosine is dependent on FGFR2, revealing EGFR family kinases to be downstream targets of amplified FGFR2. Moreover, shRNA to Erbb3 resulted in a loss of proliferation, confirming a functional role for the activated EGFR signaling pathway. These results reveal that both the FGFR2 and EGFR family signaling pathways are activated in FGFR2-amplified gastric cancer cell lines to drive cell proliferation and survival. Inhibitors of FGFR2 or Erbb3 signaling may have therapeutic efficacy in the subset of gastric cancers containing FGFR2 amplification. [Cancer Res 2008;68(7):2340–8]

This article has been cited by other articles:

				U. McDermott and J. Settleman Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology J. Clin. Oncol., November 20, 2009; 27(33): 5650 - 5659. [Abstract] [Full Text] [PDF]

				Y.-K. Yoon, H.-P. Kim, S.-W. Han, H.-S. Hur, D. Y. Oh, S.-A. Im, Y.-J. Bang, and T.-Y. Kim Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells Mol. Cancer Ther., September 1, 2009; 8(9): 2526 - 2536. [Abstract] [Full Text] [PDF]

				S. Ota, Z.-Q. Zhou, J. M. Link, and P. J. Hurlin The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects Hum. Mol. Genet., July 15, 2009; 18(14): 2609 - 2621. [Abstract] [Full Text] [PDF]

				K. Thress, T. MacIntyre, H. Wang, D. Whitston, Z.-Y. Liu, E. Hoffmann, T. Wang, J. L. Brown, K. Webster, C. Omer, et al. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway Mol. Cancer Ther., July 1, 2009; 8(7): 1818 - 1827. [Abstract] [Full Text] [PDF]

				M. Hayashi, M. Inokuchi, Y. Takagi, H. Yamada, K. Kojima, J. Kumagai, T. Kawano, and K. Sugihara High Expression of HER3 Is Associated with a Decreased Survival in Gastric Cancer Clin. Cancer Res., December 1, 2008; 14(23): 7843 - 7849. [Abstract] [Full Text] [PDF]

				S. A. Byron, M. G. Gartside, C. L. Wellens, M. A. Mallon, J. B. Keenan, M. A. Powell, P. J. Goodfellow, and P. M. Pollock Inhibition of Activated Fibroblast Growth Factor Receptor 2 in Endometrial Cancer Cells Induces Cell Death Despite PTEN Abrogation Cancer Res., September 1, 2008; 68(17): 6902 - 6907. [Abstract] [Full Text] [PDF]

				Correction: FGFR2 Dependence of Gastric Cancer Cell Lines Cancer Res., May 1, 2008; 68(9): 3549 - 3549. [Full Text] [PDF]